Analysts await Fate Therapeutics, Inc. (NASDAQ:FATE) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.28 EPS, up 35.71% or $0.1 from last year’s $-0.38 per share.

At the moment 6 analysts are watching Fate Therapeutics, Inc. (NASDAQ:FATE), 3 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 5 analysts have a mean sales target of 0.82 million. For the quarter ending Sep-16, 5 analysts have a mean sales target of 0.84 million whilst for the year ending Dec-16, 6 analysts have a mean target of 3.37 million.

In terms of earnings per share, 5 analysts have a -0.30 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 5 analysts have a -0.31 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of -1.19 EPS.

The biggest institutional shareholders in Fate Therapeutics, Inc. include Fidelity Management and Research Company which owns 4 million shares in the company valued at $14.52 million. Kingdon Capital Management LLC is the second biggest holder with 3 million shares currently valued at 8.75 million whilst ARCH Venture Partners has 2 million shares valued at 12.07 million.

Total shares held by institutions as of the most recent company filings are 22,628,967 with a reported 2,055,469 bought and 338,896 sold. These holdings make up 78.79% of the company’s outstanding shares.

Currently insiders hold 537,399 shares in the business which makes up 1.86% of shares. The biggest holder currently is Dr. John D. Mendlein who owns 156,774 shares (0.54% of those outstanding), whilst Mr. J. Scott Wolchko holds 139,479 (0.48% of shares outstanding) and Daniel D. Shoemaker holds 103,816 (0.36% of shares outstanding).

The stock increased 1.18% or $0.02 during the last trading session, hitting $2.49. Fate Therapeutics, Inc. (NASDAQ:FATE) has fallen 95.18% over the past 6 months and is downtrending.